SLCO1B1 Variant (Val174Ala)

If a statin has ever left you with unexplained muscle aches, or if you are about to start one for the first time, your genes may be part of the story. A single letter change in a gene called SLCO1B1 can slow how quickly your liver clears statins from your blood, letting drug levels build up and increasing the odds of muscle side effects. The variant is common, permanent, and easy to test once.

This test looks at Val174Ala (also written as rs4149056 or c.521T>C), the SLCO1B1 change with the strongest evidence linking genetics to statin intolerance. Knowing your result before you fill a statin prescription can change which drug and dose your clinician chooses, and it can help make sense of muscle symptoms if you have already tried one.

What SLCO1B1 Actually Does

The SLCO1B1 gene tells your liver how to build OATP1B1, a doorway on the surface of liver cells that pulls drugs and natural molecules out of the blood and into the liver so they can be processed. Statins are one of its main passengers. When that doorway works normally, statin levels in your bloodstream stay in the range they were designed to. When the doorway is slower, more of the drug lingers in your blood and reaches your muscles, where the most common statin side effects appear.

Val174Ala is a small change in the code for that doorway. In laboratory studies of the transporter, this change lowered the amount of working protein sitting at the liver cell surface, and in some experiments it dropped transporter activity substantially. The exact size of the drop varies by test system, but the direction is consistent: less transport into the liver, more drug in the blood.

Statin Intolerance and Muscle Symptoms

The clearest human evidence for Val174Ala is with simvastatin. In a study of 229 healthy volunteers, people whose SLCO1B1 function fell into the poor category had simvastatin acid levels in their blood that were 273% larger than people with normal function. In routine diabetes care, carrying the Val174Ala change was linked to roughly twice the odds of statin intolerance, meaning switching statins, stopping treatment, or reporting side effects.

In a Scottish cohort (reported in a preprint/conference analysis and not yet in a fully peer-reviewed publication), people with high-risk SLCO1B1 haplotypes had 2.42 times the odds of general statin intolerance, 2.51 times the odds of statin-related myopathy, and 2.85 times the odds of suspected rhabdomyolysis compared with lower-risk carriers. A meta-analysis across 11,246 statin users found that Val174Ala carriers had a stronger signal for side effects with simvastatin specifically, with a pooled effect of about 3.43 in simvastatin users.

For high statin doses, the story is even more compelling. In people taking 40 mg or more per day, homozygous Val174Ala carriers had roughly 2.5 times the risk of general statin intolerance and about 3 times the risk of statin-related myopathy, with symptoms tending to appear earlier in the course of treatment.

Not All Statins Are Equal

The strength of the Val174Ala signal depends heavily on which statin you take. Simvastatin has the most consistent link, followed by atorvastatin, with pravastatin, rosuvastatin, and fluvastatin generally showing weaker associations. For atorvastatin, evidence is mixed: one large electronic-record study found each copy of the reduced-function variant raised the odds of stopping atorvastatin by 22%, while a much larger analysis of the ODYSSEY OUTCOMES trial found no link between Val174Ala and muscle symptoms in people taking high-intensity atorvastatin or rosuvastatin, with an odds ratio of 1.03.

For rosuvastatin, one case-control study found that people with side effects were about 2.2 to 2.5 times more likely to carry the variant, but the ODYSSEY OUTCOMES analysis did not confirm this in a much larger population. The practical takeaway: your Val174Ala result matters most for decisions about simvastatin, is relevant but softer for atorvastatin, and less decisive for pravastatin and rosuvastatin, which are among the statins current guidelines actually recommend as safer alternatives for reduced-function carriers.

Beyond Statins

OATP1B1 carries other drugs into the liver too, and Val174Ala can change how they behave. In pediatric acute lymphoblastic leukemia patients receiving high-dose methotrexate, SLCO1B1 variants have been repeatedly linked to slower methotrexate clearance, higher exposure, and greater risk of severe toxicity. The variants most consistently associated with methotrexate clearance in these studies (rs11045879 and rs4149081) sit very close to rs4149056 and are usually inherited together with it, so a Val174Ala result gives useful, if indirect, information about methotrexate handling. For the blood pressure drug enalapril, a single Chinese study found that carrying the 521C allele roughly doubled the risk of enalapril-induced cough, with a clear gene-dose pattern: 28.2% of non-carriers had cough versus 71.4% of people with two copies. This finding needs replication in other populations.

In one small study of people with cirrhosis on statins, carrying the reduced-function variant appeared to blunt some benefits: variant carriers had more esophageal varices (odds ratio 2.68) and more bacterial infections (odds ratio 2.50) than wild-type carriers on statins. These findings come from a single small cohort and are much less mature than the statin muscle-symptom data, but they hint that the same transporter change ripples through several drug classes.

Reconciling the Mixed Evidence

It can look confusing that Val174Ala predicts side effects strongly in some studies and weakly or not at all in others. The most likely explanation is that Val174Ala on its own is an incomplete picture of your OATP1B1 activity. The SLCO1B1 gene has several other common variants, some of which increase transporter function and offset the effect of Val174Ala. Studies that use only rs4149056 group people who actually have normal function together with people who have reduced function, which dilutes the signal.

Some analyses suggest that testing Val174Ala alone can misclassify a meaningful share of statin users compared with more complete genotyping, though the exact figure comes from preprint data and has not been independently confirmed in peer-reviewed literature. Newer approaches that combine four SLCO1B1 variants into a single risk score line up more consistently with intolerance, myopathy, and rhabdomyolysis outcomes than Val174Ala by itself. Your Val174Ala result is a starting point rather than the last word.

How This Result Fits Into Your Care

Val174Ala is one of the best-established pharmacogenetic variants in cardiovascular care. Pharmacogenetics guidelines (including CPIC and the VA/DoD) recognize it, particularly for simvastatin, but the field is still refining who benefits most and how to combine it with other variants. If you carry two copies of the reduced-function allele, current prescribing guidance often recommends starting simvastatin at a lower dose or choosing a different statin. Heterozygous carriers warrant caution and closer follow-up during the first months of a new statin.

For anyone who has been called statin-intolerant, the result can also reopen options. In a randomized trial in previously statin-intolerant patients, sharing SLCO1B1 results with their clinician led to more new statin prescriptions (55.4% vs 38.0%) and lower LDL cholesterol at three months. A separate randomized trial in statin-naive adults found that preemptive testing was noninferior for LDL reduction and shifted prescribing away from simvastatin in decreased-function carriers. Knowing which statin is more likely to be tolerated can put people back on effective heart-disease prevention rather than nothing at all.

One-Time Result, Lifetime Use

Val174Ala is a permanent part of your DNA, so this is a one-time test. Your genotype does not need to be repeated, and it will not change with age, diet, or medication. The value comes from having the answer on file for every future prescribing decision, not from tracking any trend over time.

What should be tracked over time is what your genotype affects: your LDL cholesterol response to any statin you start, muscle symptoms you notice in the first months of treatment, and creatine kinase (a muscle enzyme) if symptoms appear. A sensible cadence is a baseline lipid panel before starting a statin, a repeat at three months to confirm the drug is working and tolerated, then at least annually. If muscle symptoms develop, a CK test is worth adding.

Decision Pathway for an Abnormal Result

If your result shows one or two copies of the Val174Ala variant, the next steps depend on where you are in your statin journey. If you are statin-naive and considering one for cardiovascular prevention, share the result with the clinician who will prescribe it. Simvastatin at doses above 20 mg is the clearest pattern to reconsider. Pravastatin, atorvastatin, rosuvastatin, and pitavastatin are alternatives, with rosuvastatin (at 5 to 10 mg) and pravastatin (at 40 mg) placed in the lowest-risk category for reduced- and poor-function carriers in the VA/DoD 2025 guideline.

If you have already tried a statin and had muscle pain or weakness, the result can help distinguish a nocebo effect from a genuine pharmacogenetic vulnerability. Pairing an abnormal Val174Ala result with a persistently elevated creatine kinase during statin treatment strengthens the case for switching drugs. Companion tests that add clarity include a lipid panel with ApoB or Lp(a) to gauge how aggressively LDL needs to come down, a CK to detect muscle injury, and liver enzymes if hepatic symptoms appear. Broader SLCO1B1 sequencing or a pharmacogenetic panel can identify additional variants, especially in people of African ancestry, where variants beyond rs4149056 explain a meaningful share of statin risk. A cardiologist, lipidologist, or clinical pharmacogenetics specialist is the right partner for complex cases.

What About Your Family

SLCO1B1 variants follow the usual patterns of inheritance, so first-degree relatives (parents, siblings, and children) have a meaningful chance of carrying the same change. If you test positive, letting family members who take or may need statins know about the result can help them avoid a rocky introduction to a drug most people tolerate well. This is especially useful in families with a history of muscle problems on statins, unexplained statin discontinuation, or elevated CK.

When Results Can Be Misleading

Genetic tests are stable, but a few things can still trip up interpretation. Variant panel coverage is the first: many commercial tests report only rs4149056 and miss other SLCO1B1 variants that meaningfully change transporter function. A negative result rules out this specific change but not every reduced-function or gain-of-function variant in the gene.

Ancestry matters. In a large study of Black participants, rare loss-of-function variants (rs77271279 and rs59502379) were more strongly linked to elevated bilirubin, a marker of reduced OATP1B1 function, than rs4149056 itself. If you have recent Sub-Saharan African ancestry and a negative Val174Ala result, a broader SLCO1B1 panel is a reasonable next step. Similarly, in one Saudi population study, rare and novel variants had a combined frequency of 2.3% and would be missed by SNP-only testing.

Direct-to-consumer genetic reports sometimes flag rs4149056, but these are typically not clinical-grade. If a lifestyle test is your only data point and a statin decision is on the line, a confirmatory clinical assay is worth the extra step.